1 study found for:    EPAS1
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Conditions: Childhood High-grade Cerebral Astrocytoma;   Childhood Oligodendroglioma;   Childhood Spinal Cord Neoplasm;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma
Interventions: Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Radiation: fludeoxyglucose F 18

Indicates status has not been verified in more than two years